Topper Copies

You are the Director of the National Bioethics Commission who is responsible for assessing the ethical feasibility and oversight of a nationwide gene sequencing program. The project named GeneFuture, aims to sequence the DNA of every newborn child and store it in a centralized national database. The objective is to identify genetic predispositions to serious diseases early in life, allowing for preventive treatment and personalized medicine. Over 100,000 babies have already been enrolled in the pilot phase of the program. The government claims that this move is a landmark step in public health advancement. However, collection of newborn genetic data raises significant ethical concerns, particularly around informed consent, which may not fully capture parents' understanding of the long-term risks involved. Once gathered, this sensitive data could be misused for purposes such as surveillance, insurance discrimination, or commercial marketing by third parties. Uncertainty over data ownership\xe2\x80\x94whether it lies with the state, parents, or the individual as they mature\xe2\x80\x94further complicates the issue. The involvement of private tech and pharmaceutical companies heightens fears of commercial exploitation, especially in the absence of clear mechanisms for individuals to withdraw consent or delete their genetic information upon reaching adulthood. (a) What are the ethical issues you perceive in the implementation of the GeneFuture program? (b) Identify the conflicting interests of different stakeholders in this case. (c) What guiding ethical principles would you recommend for implementation of this project?

Apurva Verma, AIR 42, 2025

The above case-study point towards rising developments in the field of science and technology and associated privacy issues for the citizens. There is a need to deal with the matter in a comprehensive manner in the backdrop of increasing pace of development

Stakeholders involved

1. Newborn babies and their parents 2. Government 3. Pharmaceutical and private tech companies 4. Director, National Bioethics committee 5. Media

(a) Ethical issues perceived

1. Right to privacy of newborn infants. 2. Misuse by pharmaceutical and private tech companies 3. Ambiguity in withdrawal of consent. 4. Unawareness of parents of newborns. 5. Futuristic technologies may use data not consented for.

(b) Conflicting interests between stakeholders

| Government | People | |---|---| | Research on data of infants | Right to privacy being compromised. | | No transparency in usage of data. | Not provided with clear terms and conditions | | No grievance redressal mechanism | May be difficult in case of misuse |

| Pvt. companies | People | |---|---| | May diversify use of data without consent | No provision for withdrawal of consent when infants turn adult. | | May commercialise the data. | |

(c) Guiding ethical principles

1. Citizen-centric policy to be framed for such utilisation of genetic data. - Eg: EU's GPDR Act. 2. Heavy fines and strict action against officials found violating terms and conditions - Eg: Inclusion under BNS. 3. License cancellation for private companies not adhering to consent. 4. Right to be forgotten to be amplified in all such programs. 5. Time-bound storing of data. - Mandatory destruction after certain time. 6. Randomisation and anonymisation of data

With evolutionary technologies, there is a need to protect citizen's interests to safeguard both scientific development and personal well-being.